![]() |
Name |
Bisorbicillinolide
|
Molecular Formula | C28H32O8 | |
IUPAC Name* |
(1R,2S,3S,6R,7S,8R,10Z,11S,12S)-1-[(2E,4E)-hexa-2,4-dienoyl]-7,12-dihydroxy-10-[(2E,4E)-1-hydroxyhexa-2,4-dienylidene]-3,6,8,12-tetramethyl-4-oxatetracyclo[6.5.0.02,11.03,7]tridecane-5,9,13-trione
|
|
SMILES |
C/C=C/C=C/C(=C/1\[C@@H]2[C@@H]3[C@]4([C@]([C@H](C(=O)O4)C)([C@](C1=O)([C@@]3(C(=O)[C@@]2(C)O)C(=O)/C=C/C=C/C)C)O)C)/O
|
|
InChI |
InChI=1S/C28H32O8/c1-7-9-11-13-16(29)18-19-20-26(6)28(35,15(3)22(32)36-26)25(5,21(18)31)27(20,23(33)24(19,4)34)17(30)14-12-10-8-2/h7-15,19-20,29,34-35H,1-6H3/b9-7+,10-8+,13-11+,14-12+,18-16-/t15-,19+,20+,24-,25+,26-,27-,28-/m0/s1
|
|
InChIKey |
XNZGICAZEJYYNT-TUECVNBISA-N
|
|
Synonyms |
Bisorbicillinolide; 220327-40-2
|
|
CAS | NA | |
PubChem CID | 101000962 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 496.5 | ALogp: | 2.3 |
HBD: | 3 | HBA: | 8 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 138.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 36 | QED Weighted: | 0.173 |
Caco-2 Permeability: | -5.302 | MDCK Permeability: | 0.00003780 |
Pgp-inhibitor: | 0.99 | Pgp-substrate: | 0.06 |
Human Intestinal Absorption (HIA): | 0.014 | 20% Bioavailability (F20%): | 0.001 |
30% Bioavailability (F30%): | 0.014 |
Blood-Brain-Barrier Penetration (BBB): | 0.814 | Plasma Protein Binding (PPB): | 75.94% |
Volume Distribution (VD): | 0.645 | Fu: | 16.54% |
CYP1A2-inhibitor: | 0.003 | CYP1A2-substrate: | 0.91 |
CYP2C19-inhibitor: | 0.016 | CYP2C19-substrate: | 0.771 |
CYP2C9-inhibitor: | 0.009 | CYP2C9-substrate: | 0.021 |
CYP2D6-inhibitor: | 0 | CYP2D6-substrate: | 0.062 |
CYP3A4-inhibitor: | 0.072 | CYP3A4-substrate: | 0.918 |
Clearance (CL): | 5.599 | Half-life (T1/2): | 0.101 |
hERG Blockers: | 0.055 | Human Hepatotoxicity (H-HT): | 0.304 |
Drug-inuced Liver Injury (DILI): | 0.313 | AMES Toxicity: | 0.141 |
Rat Oral Acute Toxicity: | 0.22 | Maximum Recommended Daily Dose: | 0.938 |
Skin Sensitization: | 0.865 | Carcinogencity: | 0.797 |
Eye Corrosion: | 0.014 | Eye Irritation: | 0.027 |
Respiratory Toxicity: | 0.973 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003250 | ![]() |
0.583 | D0FG6M | ![]() |
0.232 | ||
ENC003709 | ![]() |
0.524 | D0E9KA | ![]() |
0.204 | ||
ENC005987 | ![]() |
0.516 | D0H2MO | ![]() |
0.203 | ||
ENC004472 | ![]() |
0.492 | D0KR9U | ![]() |
0.199 | ||
ENC003579 | ![]() |
0.484 | D0G3PI | ![]() |
0.194 | ||
ENC003500 | ![]() |
0.484 | D00DKK | ![]() |
0.194 | ||
ENC003762 | ![]() |
0.404 | D02DGU | ![]() |
0.194 | ||
ENC003887 | ![]() |
0.399 | D0G6AB | ![]() |
0.189 | ||
ENC004085 | ![]() |
0.397 | D05QDC | ![]() |
0.187 | ||
ENC002144 | ![]() |
0.391 | D0I5DS | ![]() |
0.183 |